Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
- Mechanism
- Curator reviewed
Through complete blockade of tissular endothelin, Actelion-1 is expected to protect tissue from the damaging effect of elevated endothelin, specifically in the cardiovascular system. In pre-clinical studies, Actelion-1 also exhibited effects suggesting that it maintains the integrity of the vascular wall and improves long-term outcome. Accordingly, Actelion-1 may provide therapeutic benefit in a wide range of cardiovascular indications.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders, hypertension, and pulmonary hypertension.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Actelion-1, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account